Zacks: Brokerages Anticipate Amyris Inc (AMRS) Will Post Quarterly Sales of $37.53 Million


Wall Street brokerages expect that Amyris Inc (NASDAQ:AMRS) will post $37.53 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Amyris’ earnings. The lowest sales estimate is $37.00 million and the highest is $38.05 million. Amyris reported sales of $25.68 million during the same quarter last year, which indicates a positive year over year growth rate of 46.1%. The firm is scheduled to issue its next quarterly earnings results on Thursday, August 9th.

According to Zacks, analysts expect that Amyris will report full year sales of $188.09 million for the current financial year, with estimates ranging from $185.58 million to $190.60 million. For the next fiscal year, analysts expect that the firm will report sales of $277.28 million per share, with estimates ranging from $254.85 million to $299.70 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Amyris.


Get Amyris alerts:

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.31). The company had revenue of $23.00 million for the quarter, compared to the consensus estimate of $24.12 million. The business’s revenue was up 77.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) earnings per share.

AMRS has been the topic of several recent research reports. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Wednesday, April 25th. BidaskClub downgraded shares of Amyris from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 17th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Amyris in a report on Monday, April 2nd. B. Riley set a $10.00 price objective on shares of Amyris and gave the company a “buy” rating in a report on Tuesday, March 20th. Finally, ValuEngine raised shares of Amyris from a “hold” rating to a “buy” rating in a report on Monday, May 7th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Amyris presently has a consensus rating of “Buy” and an average price target of $9.13.


Amyris traded down $0.15, hitting $5.03, during trading on Thursday, according to MarketBeat Ratings. 670,852 shares of the company’s stock traded hands, compared to its average volume of 785,962. The company has a market cap of $252.39 million, a PE ratio of -1.65 and a beta of 0.15. Amyris has a 12-month low of $1.86 and a 12-month high of $7.30. The company has a quick ratio of 0.93, a current ratio of 0.67 and a debt-to-equity ratio of -0.35.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $6.54, for a total value of $622,359.48. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 21.80% of the company’s stock.


Several institutional investors have recently made changes to their positions in the company. KBC Group NV lifted its holdings in shares of Amyris by 37.4% in the first quarter. KBC Group NV now owns 62,465 shares of the biotechnology company’s stock worth $418,000 after buying an additional 16,995 shares in the last quarter. BlackRock Inc. increased its position in shares of Amyris by 139.2% in the first quarter. BlackRock Inc. now owns 53,414 shares of the biotechnology company’s stock worth $358,000 after purchasing an additional 31,083 shares during the last quarter. Element Capital Management LLC bought a new position in shares of Amyris in the first quarter worth approximately $227,000. Compagnie Lombard Odier SCmA increased its position in shares of Amyris by 60.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares during the last quarter. Finally, B. Riley Financial Inc. bought a new position in shares of Amyris in the first quarter worth approximately $294,000. 23.95% of the stock is currently owned by hedge funds and other institutional investors.


About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amyris (NASDAQ:AMRS)

Leave a Reply

Your email address will not be published.